Accuracy and prognostic impact of <scp>FDG PET</scp> / <scp>CT</scp> and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A <scp>Nation‐Wide</scp> cohort study

In the workup of follicular lymphoma (FL), bone marrow biopsy (BMB) assessment is a key component of FLIPI and FLIPI2, the most widely used outcome scores. During the previous decade, several studies explored the role of FDG-PET/CT for detecting nodal and extranodal disease, with only one large study comparing both techniques.The aim of our study was to evaluate the diagnostic accuracy and the prognostic impact of both procedures in a retrospective cohort of 299 FL patients with both tests performed at diagnosis. In order to avoid a collinearity bias, FLIPI2 was deconstructed in its founding parameters, and the bone marrow involvement (BMI) parameter separately included as: a positive BMB, a positive PET/CT, the combined &quot;PET/CT and BMB positive&quot; or &quot;PET/CT or BMB positive&quot;. These variables were also confronted independently with the POD24 in 233 patients treated with intensive regimens.In the total cohort, bone marrow was involved in 124 and 60 patients by BMB and PET/CT, respectively. In terms of overall survival, age 60 y.o. and the combined &quot;PET/CT or BMB positive&quot; achieved statistical independence as a prognostic factor. In patients treated with an intensive regimen, only the combined &quot;PET/CT or BMB positive&quot; added prognostic value for a shorter overall survival, when confronted with the POD24.Our results show that in FL both BMB and PET/CT should be considered at diagnosis, as their combined assessment provides independent prognostic value in the context of the most widely use clinical scores.